

Mihajlo Michael Jakovljevic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6779192/publications.pdf>

Version: 2024-02-01

219
papers

90,456
citations

15466

65
h-index

1589

216
g-index

241
all docs

241
docs citations

241
times ranked

109277
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1789-1858. | 6.3 | 8,569 |
| 2 | Global burden of 369 diseases and injuries in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1204-1222. | 6.3 | 7,664 |
| 3 | Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1211-1259. | 6.3 | 5,578 |
| 4 | Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1545-1602. | 6.3 | 5,298 |
| 5 | Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1736-1788. | 6.3 | 4,989 |
| 6 | Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1459-1544. | 6.3 | 4,934 |
| 7 | Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015. <i>JAMA Oncology</i> , 2017, 3, 524. | 3.4 | 4,254 |
| 8 | Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1659-1724. | 6.3 | 4,203 |
| 9 | Global burden of 87 risk factors in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1223-1249. | 6.3 | 3,928 |
| 10 | Global, regional, and national age-sex specific mortality for 264 causes of death, 1980â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1151-1210. | 6.3 | 3,565 |
| 11 | Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1923-1994. | 6.3 | 3,269 |
| 12 | Global, regional, and national burden of neurological disorders, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 459-480. | 4.9 | 2,625 |
| 13 | Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1859-1922. | 6.3 | 2,123 |
| 14 | Alcohol use and burden for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 392, 1015-1035. | 6.3 | 2,005 |
| 15 | Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1345-1422. | 6.3 | 1,879 |
| 16 | Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. <i>JAMA Oncology</i> , 2019, 5, 1749. | 3.4 | 1,691 |
| 17 | Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet Respiratory Medicine, the</i> , 2017, 5, 691-706. | 5.2 | 1,672 |
| 18 | Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1260-1344. | 6.3 | 1,589 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Global, regional, and national burden of neurological disorders during 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet Neurology, The</i> , 2017, 16, 877-897. | 4.9 | 1,521 |
| 20 | Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016. <i>JAMA Oncology</i> , 2018, 4, 1553. | 3.4 | 1,260 |
| 21 | Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Infectious Diseases, The</i> , 2018, 18, 1191-1210. | 4.6 | 1,084 |
| 22 | Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 56-87. | 4.9 | 1,064 |
| 23 | Prevalence and attributable health burden of chronic respiratory diseases, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet Respiratory Medicine,the</i> , 2020, 8, 585-596. | 5.2 | 1,049 |
| 24 | Global, regional, and national levels of maternal mortality, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1775-1812. | 6.3 | 740 |
| 25 | Global, regional, and national age-sex-specific mortality and life expectancy, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1684-1735. | 6.3 | 716 |
| 26 | Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271. | 6.3 | 638 |
| 27 | Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990â€“2019: a systematic analysis from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2021, 397, 2337-2360. | 6.3 | 609 |
| 28 | Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1084-1150. | 6.3 | 573 |
| 29 | Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016. <i>BMJ: British Medical Journal</i> , 2019, 364, l94. | 2.4 | 558 |
| 30 | Global, regional, and national burden of epilepsy, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 357-375. | 4.9 | 526 |
| 31 | Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990â€“2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 390, 231-266. | 6.3 | 480 |
| 32 | Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€“2015: the Global Burden of Disease Study 2015. <i>Lancet HIV,the</i> , 2016, 3, e361-e387. | 2.1 | 461 |
| 33 | Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850. | 6.3 | 413 |
| 34 | Global Burden of Multiple Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1221. | 3.4 | 398 |
| 35 | Global, regional, and national burden of brain and other CNS cancer, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 376-393. | 4.9 | 359 |
| 36 | Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 2091-2138. | 6.3 | 335 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Five insights from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1135-1159. | 6.3 | 335 |
| 38 | Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1250-1284. | 6.3 | 330 |
| 39 | Child and Adolescent Health From 1990 to 2015. <i>JAMA Pediatrics</i> , 2017, 171, 573. | 3.3 | 306 |
| 40 | Population and fertility by age and sex for 195 countries and territories, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1995-2051. | 6.3 | 294 |
| 41 | Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1423-1459. | 6.3 | 284 |
| 42 | Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995â€“2050. <i>Lancet, The</i> , 2019, 393, 2233-2260. | 6.3 | 283 |
| 43 | The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 913-933. | 3.7 | 259 |
| 44 | Evolution and patterns of global health financing 1995â€“2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. <i>Lancet, The</i> , 2017, 389, 1981-2004. | 6.3 | 204 |
| 45 | Global Mortality From Firearms, 1990-2016. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 792. | 3.8 | 189 |
| 46 | Global, regional, and national burden of colorectal cancer and its risk factors, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 627-647. | 3.7 | 177 |
| 47 | Future and potential spending on health 2015â€“40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. <i>Lancet, The</i> , 2017, 389, 2005-2030. | 6.3 | 163 |
| 48 | Evolving Health Expenditure Landscape of the BRICS Nations and Projections to 2025. <i>Health Economics (United Kingdom)</i> , 2017, 26, 844-852. | 0.8 | 141 |
| 49 | Comparative financing analysis and political economy of noncommunicable diseases. <i>Journal of Medical Economics</i> , 2019, 22, 722-727. | 1.0 | 140 |
| 50 | Mapping child growth failure across low- and middle-income countries. <i>Nature</i> , 2020, 577, 231-234. | 13.7 | 128 |
| 51 | Growing Burden of Non-Communicable Diseases in the Emerging Health Markets: The Case of BRICS. <i>Frontiers in Public Health</i> , 2015, 3, 65. | 1.3 | 109 |
| 52 | Real GDP growth rates and healthcare spending â€“ comparison between the G7 and the EM7 countries. <i>Globalization and Health</i> , 2020, 16, 64. | 2.4 | 109 |
| 53 | Resource allocation strategies in Southeastern European health policy. <i>European Journal of Health Economics</i> , 2013, 14, 153-159. | 1.4 | 107 |
| 54 | <p>Predictors of (in)efficiencies of Healthcare Expenditure Among the Leading Asian Economies â€“ Comparison of OECD and Non-OECD Nations</p>. <i>Risk Management and Healthcare Policy</i> , 2020, Volume 13, 2261-2280. | 1.2 | 103 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017. <i>Injury Prevention</i> , 2020, 26, i96-i114. | 1.2 | 103 |
| 56 | Growth of Global Health Spending Share in Low and Middle Income Countries. <i>Frontiers in Pharmacology</i> , 2016, 7, 21. | 1.6 | 99 |
| 57 | Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2021, 398, 1593-1618. | 6.3 | 92 |
| 58 | Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17. <i>The Lancet Global Health</i> , 2020, 8, e1162-e1185. | 2.9 | 91 |
| 59 | Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. <i>Lancet, The</i> , 2020, 396, 693-724. | 6.3 | 87 |
| 60 | Morbidity and mortality from road injuries: results from the Global Burden of Disease Study 2017. <i>Injury Prevention</i> , 2020, 26, i46-i56. | 1.2 | 86 |
| 61 | Life expectancy and health expenditure evolution in Eastern Europe—DiD and DEA analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 537-546. | 0.7 | 81 |
| 62 | The impact of health expenditures on public health in BRICS nations. <i>Journal of Sport and Health Science</i> , 2019, 8, 516-519. | 3.3 | 79 |
| 63 | Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990–2050. <i>Lancet, The</i> , 2021, 398, 1317-1343. | 6.3 | 79 |
| 64 | Mapping subnational HIV mortality in six Latin American countries with incomplete vital registration systems. <i>BMC Medicine</i> , 2021, 19, 4. | 2.3 | 78 |
| 65 | Comparison of historical medical spending patterns among the BRICS and G7. <i>Journal of Medical Economics</i> , 2016, 19, 70-76. | 1.0 | 76 |
| 66 | Health Economics at the Crossroads of Centuries – From the Past to the Future. <i>Frontiers in Public Health</i> , 2016, 4, 115. | 1.3 | 75 |
| 67 | Editorial: Global Population Aging - Health Care, Social and Economic Consequences. <i>Frontiers in Public Health</i> , 2018, 6, 335. | 1.3 | 73 |
| 68 | Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2020, 395, 1779-1801. | 6.3 | 72 |
| 69 | The Global South political economy of health financing and spending landscape – history and presence. <i>Journal of Medical Economics</i> , 2021, 24, 25-33. | 1.0 | 72 |
| 70 | Mapping routine measles vaccination in low- and middle-income countries. <i>Nature</i> , 2021, 589, 415-419. | 13.7 | 71 |
| 71 | Review of Diagnosis-Related Group-Based Financing of Hospital Care. <i>Health Services Research and Managerial Epidemiology</i> , 2016, 3, 233339281664789. | 0.5 | 64 |
| 72 | Global and regional burden of cancer in 2016 arising from occupational exposure to selected carcinogens: a systematic analysis for the Global Burden of Disease Study 2016. <i>Occupational and Environmental Medicine</i> , 2020, 77, 151-159. | 1.3 | 64 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Health Financing Constrained by Population Aging - An Opportunity to Learn from Japanese Experience / Finansiranje Zdravstvene Zaštite U Uslovima Starenja Populacije - Prilika Da Učimo Na Japanskom Iskustvu. Serbian Journal of Experimental and Clinical Research, 2014, 15, 175-181. | 0.2 | 62 |
| 74 | The Influence of Universal Health Coverage on Life Expectancy at Birth (LEAB) and Healthy Life Expectancy (HALE): A Multi-Country Cross-Sectional Study. Frontiers in Pharmacology, 2018, 9, 960. | 1.6 | 62 |
| 75 | BRICs' Growing Share of Global Health Spending and Their Diverging Pathways. Frontiers in Public Health, 2015, 3, 135. | 1.3 | 58 |
| 76 | Mapping disparities in education across low- and middle-income countries. Nature, 2020, 577, 235-238. | 13.7 | 58 |
| 77 | Structural Factors Responsible for Universal Health Coverage in Low- and Middle-Income Countries: Results From 118 Countries. Frontiers in Public Health, 2019, 7, 414. | 1.3 | 56 |
| 78 | Do Health Reforms Impact Cost Consciousness of Health Care Professionals? Results from a Nation-Wide Survey in the Balkans. Balkan Medical Journal, 2016, 33, 8-17. | 0.3 | 48 |
| 79 | Burden of cancer in the Eastern Mediterranean Region, 2005–2015: findings from the Global Burden of Disease 2015 Study. International Journal of Public Health, 2018, 63, 151-164. | 1.0 | 48 |
| 80 | Editorial: Health Care Financing and Affordability in the Emerging Global Markets. Frontiers in Public Health, 2016, 4, 2. | 1.3 | 47 |
| 81 | Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. Nature Medicine, 2020, 26, 750-759. | 15.2 | 47 |
| 82 | Future health spending forecast in leading emerging BRICS markets in 2030: health policy implications. Health Research Policy and Systems, 2022, 20, 23. | 1.1 | 45 |
| 83 | Evolution of the Serbian pharmaceutical market alongside socioeconomic transition. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 521-530. | 0.7 | 44 |
| 84 | Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study. Injury Prevention, 2020, 26, i125-i153. | 1.2 | 44 |
| 85 | Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. Injury Prevention, 2020, 26, i12-i26. | 1.2 | 44 |
| 86 | The burden of mental disorders in the Eastern Mediterranean region, 1990–2015: findings from the global burden of disease 2015 study. International Journal of Public Health, 2018, 63, 25-37. | 1.0 | 43 |
| 87 | Underlying Differences in Health Spending Within the World Health Organisation Europe Region—Comparing EU15, EU Post-2004, CIS, EU Candidate, and CARIN FNET Countries. International Journal of Environmental Research and Public Health, 2019, 16, 3043. | 1.2 | 42 |
| 88 | Contemporary generic market in Japan – key conditions to successful evolution. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 181-194. | 0.7 | 41 |
| 89 | Global, Regional, and National Levels of Maternal Mortality, 1990–2015: A Systematic Analysis for the Global Burden of Disease Study 2015. Obstetrical and Gynecological Survey, 2017, 72, 11-13. | 0.2 | 41 |
| 90 | Current efforts and proposals to reduce healthcare costs in Serbia. Serbian Journal of Experimental and Clinical Research, 2011, 12, 161-163. | 0.2 | 40 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | The New and Old Europe: East-West Split in Pharmaceutical Spending. <i>Frontiers in Pharmacology</i> , 2016, 7, 18. | 1.6 | 39 |
| 92 | Population aging and migration – history and UN forecasts in the EU-28 and its east and south near neighborhood – one century perspective 1950–2050. <i>Globalization and Health</i> , 2018, 14, 30. | 2.4 | 39 |
| 93 | Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. <i>Lancet Public Health</i> , The, 2021, 6, e482-e499. | 4.7 | 38 |
| 94 | The burden of disease in Greece, health loss, risk factors, and health financing, 2000–16: an analysis of the Global Burden of Disease Study 2016. <i>Lancet Public Health</i> , The, 2018, 3, e395-e406. | 4.7 | 37 |
| 95 | Cost-effectiveness and resource allocation (CERA) 18 years of evolution: maturity of adulthood and promise beyond tomorrow. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 15. | 0.6 | 36 |
| 96 | Validation of a patient satisfaction questionnaire in primary health care. <i>Public Health</i> , 2012, 126, 710-718. | 1.4 | 35 |
| 97 | Antibiotic Resistance in Syria: A Local Problem Turns Into a Global Threat. <i>Frontiers in Public Health</i> , 2018, 6, 212. | 1.3 | 35 |
| 98 | Changes in disease burden in Poland between 1990–2017 in comparison with other Central European countries: A systematic analysis for the Global Burden of Disease Study 2017. <i>PLoS ONE</i> , 2020, 15, e0226766. | 1.1 | 33 |
| 99 | COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India’s Role at the WTO Platform. <i>BioMed Research International</i> , 2021, 2021, 1-8. | 0.9 | 33 |
| 100 | Organizational measures aiming to combat COVID-19 in the Russian Federation: the first experience. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 571-576. | 0.7 | 32 |
| 101 | Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub-Saharan Africa, 2000–18: a modelling study. <i>Lancet HIV</i> , the, 2021, 8, e363-e375. | 2.1 | 32 |
| 102 | Radiology Services Costs and Utilization Patterns Estimates in Southeastern Europe – A Retrospective Analysis from Serbia. <i>Value in Health Regional Issues</i> , 2013, 2, 218-225. | 0.5 | 31 |
| 103 | The Key Role of the Leading Emerging Bric Markets in the Future of Global Health Care. <i>Serbian Journal of Experimental and Clinical Research</i> , 2014, 15, 139-143. | 0.2 | 31 |
| 104 | End-of-life costs of medical care for advanced stage cancer patients. <i>Vojnosanitetski Pregled</i> , 2015, 72, 334-341. | 0.1 | 31 |
| 105 | Asian innovation in pharmaceutical and medical device industry – beyond tomorrow. <i>Journal of Medical Economics</i> , 2021, 24, 42-50. | 1.0 | 31 |
| 106 | How China controls the Covid-19 epidemic through public health expenditure and policy?. <i>Journal of Medical Economics</i> , 2022, 25, 437-449. | 1.0 | 31 |
| 107 | Within the triangle of healthcare legacies: comparing the performance of South-Eastern European health systems. <i>Journal of Medical Economics</i> , 2017, 20, 483-492. | 1.0 | 29 |
| 108 | Radiation therapy remains the key cost driver of oncology inpatient treatment. <i>Journal of Medical Economics</i> , 2015, 18, 29-36. | 1.0 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | <p>A Country Pandemic Risk Exposure Measurement Model</p>. Risk Management and Healthcare Policy, 2020, Volume 13, 2067-2077. | 1.2 | 28 |
| 110 | Corona-Triggered Global Macroeconomic Crisis of the Early 2020s. International Journal of Environmental Research and Public Health, 2020, 17, 9404. | 1.2 | 28 |
| 111 | Community-acquired pneumonia: economics of inpatient medical care vis-À-vis clinical severity,. Jornal Brasileiro De Pneumologia, 2015, 41, 48-57. | 0.4 | 27 |
| 112 | Analysis of the Financing of Russian Health Care over the Past 100 Years. International Journal of Environmental Research and Public Health, 2019, 16, 1848. | 1.2 | 25 |
| 113 | Sustainability Challenge of Eastern Europeâ€™Historical Legacy, Belt and Road Initiative, Population Aging and Migration. Sustainability, 2021, 13, 11038. | 1.6 | 25 |
| 114 | Demographic forecasting of population aging in Greece and Cyprus: one big challenge for the Mediterranean health and social system long-term sustainability. Health Research Policy and Systems, 2021, 19, 21. | 1.1 | 24 |
| 115 | COVID-19 Pandemic: An Opportunity for Universal Health Coverage. Frontiers in Public Health, 2021, 9, 673542. | 1.3 | 24 |
| 116 | Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market. Farmeconomia E Percorsi Terapeutici, 2014, 15, 27-32. | 0.2 | 24 |
| 117 | Capitation-Based Financing Hampers the Provision of Preventive Services in Primary Health Care. Frontiers in Public Health, 2016, 4, 200. | 1.3 | 23 |
| 118 | Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countriesâ€™Forecasts to 2020. Frontiers in Public Health, 2017, 5, 23. | 1.3 | 23 |
| 119 | Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000â€™17. The Lancet Global Health, 2020, 8, e1038-e1060. | 2.9 | 23 |
| 120 | The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future. Frontiers in Public Health, 2021, 9, 671961. | 1.3 | 22 |
| 121 | A Nonlinear Mixed Effects Modelling Analysis of Topiramate Pharmacokinetics in Patients with Epilepsy. Biological and Pharmaceutical Bulletin, 2010, 33, 1176-1182. | 0.6 | 21 |
| 122 | When cure becomes an illnessâ€™abuse of addictive prescription medicines. Frontiers in Pharmacology, 2015, 6, 193. | 1.6 | 21 |
| 123 | RESILIENCE, PSYCHIATRY AND RELIGION FROM PUBLIC AND GLOBAL MENTAL HEALTH PERSPECTIVE Dialogue and Cooperation in the Search for Humanistic Self, Compassionate Society and Empathic Civilization. Psychiatria Danubina, 2017, 29, 238-244. | 0.2 | 21 |
| 124 | Access to orphan drugs â€™ comparison across Balkan countries. Health Policy, 2018, 122, 583-589. | 1.4 | 20 |
| 125 | Situation, Impacts, and Future Challenges of Tobacco Control Policies for Youth: An Explorative Systematic Policy Review. Frontiers in Pharmacology, 2019, 10, 981. | 1.6 | 20 |
| 126 | Public Health Policy of India and COVID-19: Diagnosis and Prognosis of the Combating Response. Sustainability, 2021, 13, 3415. | 1.6 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Population ageing alongside health care spending growth. Srpski Arhiv Za Celokupno Lekarstvo, 2017, 145, 534-539. | 0.1 | 20 |
| 128 | Serbian and Austrian Alcohol-Dependent Patients: A Comparison of Two Samples Regarding Therapeutically Relevant Clinical Features. Alcohol and Alcoholism, 2013, 48, 505-508. | 0.9 | 19 |
| 129 | Gross Domestic Product and Health Expenditure Growth in Balkan and East European Countries—Three-Decade Horizon. Frontiers in Public Health, 2020, 8, 492. | 1.3 | 19 |
| 130 | The aging of Europe. The unexplored potential. Farmeconomia E Percorsi Terapeutici, 2015, 16, 89-92. | 0.2 | 18 |
| 131 | Cost-Effectiveness of Ritodrine and Fenoterol for Treatment of Preterm Labor in a Low-Middle-Income Country: A Case Study. Value in Health, 2008, 11, 149-153. | 0.1 | 17 |
| 132 | Inpatient Detoxification Procedure and Facilities: Financing Considerations from an Eastern European Perspective. Alcohol and Alcoholism, 2011, 46, 364-365. | 0.9 | 17 |
| 133 | Cold War Legacy in Public and Private Health Spending in Europe. Frontiers in Public Health, 2018, 6, 215. | 1.3 | 17 |
| 134 | High Inequalities Associated With Socioeconomic Deprivation in Cardiovascular Disease Burden and Antihypertensive Medication in Hungary. Frontiers in Pharmacology, 2018, 9, 839. | 1.6 | 17 |
| 135 | The Evaluation of Antibiotic Consumption at the Inpatient Level in Kazakhstan from 2011 to 2018. Antibiotics, 2020, 9, 57. | 1.5 | 17 |
| 136 | Budget Impact of Publicly Reimbursed Prescription Medicines in the Republic of Srpska. Frontiers in Public Health, 2015, 3, 213. | 1.3 | 16 |
| 137 | Self-Assessed Health and Socioeconomic Inequalities in Serbia: Data from 2013 National Health Survey. Frontiers in Pharmacology, 2016, 7, 140. | 1.6 | 16 |
| 138 | A Correlation Study of the Colorectal Cancer Statistics and Economic Indicators in Selected Balkan Countries. Frontiers in Public Health, 2020, 8, 29. | 1.3 | 16 |
| 139 | Health expenditure dynamics in Serbia 1995-2012. Hospital Pharmacology, 2014, 1, 180-183. | 0.1 | 16 |
| 140 | Can Didactic Continuing Education Improve Clinical Decision Making and Reduce Cost of Quality? Evidence From a Case Study. Journal of Continuing Education in the Health Professions, 2015, 35, 109-118. | 0.4 | 15 |
| 141 | Accessibility and Affordability of Alcohol Dependency Medical Care in Serbia. Frontiers in Psychiatry, 2014, 5, 192. | 1.3 | 15 |
| 142 | LAT Software Induced Savings on Medical Costs of Alcohol Addicts' Care - Results from a Matched-Pairs Case-Control Study. PLoS ONE, 2014, 9, e111931. | 1.1 | 15 |
| 143 | Sanitary and Hygienic Aspects of the COVID-19 Self-isolation. Open Public Health Journal, 2020, 13, 734-738. | 0.1 | 15 |
| 144 | Direct medical costs of COPD diagnosis and treatment, Eastern vs Western European country – examples of Serbia and Belgium. Farmeconomia E Percorsi Terapeutici, 2013, 14, 161-168. | 0.2 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Impact of imaging diagnostics on the budget—are we spending too much?. <i>Vojnosanitetski Pregled</i> , 2013, 70, 709-11. | 0.1 | 15 |
| 146 | Cross-sectional survey on complementary and alternative medicine awareness among health care professionals and students using CHBQ questionnaire in a Balkan country. <i>Chinese Journal of Integrative Medicine</i> , 2013, 19, 650-655. | 0.7 | 13 |
| 147 | CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 439-445. | 0.8 | 13 |
| 148 | High Out-of-Pocket Health Spending in Countries With a Mediterranean Connection. <i>Frontiers in Public Health</i> , 2018, 6, 145. | 1.3 | 13 |
| 149 | Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future. <i>Current Medical Research and Opinion</i> , 2021, 37, 1529-1545. | 0.9 | 13 |
| 150 | A Proactive Approach to Identify the Exposure Risk to COVID-19: Validation of the Pandemic Risk Exposure Measurement (PREM) Model Using Real-World Data. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 4775-4787. | 1.2 | 13 |
| 151 | Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma. <i>Journal of B U on</i> , 2014, 19, 1111-20. | 0.4 | 13 |
| 152 | Inverse correlation of valproic acid serum concentrations and quality of life in adolescents with epilepsy. <i>Epilepsy Research</i> , 2008, 80, 180-183. | 0.8 | 12 |
| 153 | Five-year survival and costs of care in metastatic colorectal cancer: conventional versus monoclonal antibody-based treatment protocols. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 963-970. | 1.1 | 12 |
| 154 | Satisfaction with Health Services among the Citizens of Serbia. <i>Frontiers in Pharmacology</i> , 2017, 8, 50. | 1.6 | 12 |
| 155 | Analysis and Forecasting Incidence, Intensive Care Unit Admissions, and Projected Mortality Attributable to COVID-19 in Portugal, the UK, Germany, Italy, and France: Predictions for 4 Weeks Ahead. <i>Bioengineering</i> , 2021, 8, 84. | 1.6 | 12 |
| 156 | Prevalence of COVID-19 Pandemic, Self-Esteem and Its Effect on Depression Among University Students in Saudi Arabia. <i>Frontiers in Public Health</i> , 2022, 10, 836688. | 1.3 | 12 |
| 157 | Gap analysis in manufacturing, innovation and marketing of medical devices in the Asia-Pacific region. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 1043-1050. | 0.7 | 12 |
| 158 | Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-21± + Ribavirine Treated Chronic Hepatitis C Patients. <i>Hepatitis Monthly</i> , 2013, 13, e6750. | 0.1 | 11 |
| 159 | Growth of Global Publishing Output of Health Economics in the Twenty-First Century: A Bibliographic Insight. <i>Frontiers in Public Health</i> , 2017, 5, 211. | 1.3 | 11 |
| 160 | Economics of cancer related medical care: Worldwide estimates and available domestic evidence. <i>Archive of Oncology</i> , 2011, 19, 59-63. | 0.2 | 11 |
| 161 | The key role of the leading emerging BRIC markets in the future of global health care. <i>Serbian Journal of Experimental and Clinical Research</i> , 2014, 15, 139-143. | 0.2 | 11 |
| 162 | Commentary: Patient Cost Sharing and Medical Expenditures for the Elderly. <i>Frontiers in Pharmacology</i> , 2016, 7, 73. | 1.6 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Pharmaceutical expenditure dynamics in the Balkan countries. <i>Journal of Medical Economics</i> , 2017, 20, 1013-1017. | 1.0 | 10 |
| 164 | Alcohol Consumption among the Elderly Citizens in Hungary and Serbia – Comparative Assessment. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1289. | 1.2 | 10 |
| 165 | A ten-year study of depressive symptoms in Serbian medical students. <i>Acta Clinica Croatica</i> , 2013, 52, 157-63. | 0.1 | 10 |
| 166 | Effect of exogenous glutamate and Na ⁺ Methyl-D-aspartic acid on spontaneous activity of isolated human ureter. <i>International Journal of Urology</i> , 2007, 14, 833-837. | 0.5 | 9 |
| 167 | Macroeconomic Policy Impact On Oncology-Related Public Expenditure In An Emerging European Market – Signs Of Early Recovery. <i>Serbian Journal of Experimental and Clinical Research</i> , 2015, 16, 43-50. | 0.2 | 9 |
| 168 | Local Anesthesia in Pediatric Patients – a Review of Current and Alternative Methods, Devices and Techniques. <i>Folia Medica</i> , 2018, 60, 381-388. | 0.2 | 9 |
| 169 | Maternal mortality and morbidity burden in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 47-61. | 1.0 | 9 |
| 170 | Promises and Hurdles of Medical Tourism Development in the Russian Federation. <i>Frontiers in Psychology</i> , 2020, 11, 1380. | 1.1 | 9 |
| 171 | Editorial: NCDs – Core Challenge of Modern Day Health Care Establishments. <i>Frontiers in Public Health</i> , 2021, 9, 692926. | 1.3 | 9 |
| 172 | Therapeutic innovations: the future of health economics and outcomes research – increasing role of the Asia-Pacific. <i>Journal of Medical Economics</i> , 2021, 24, (i)-(iii). | 1.0 | 9 |
| 173 | A Global Assessment of Sustainable Development: Integrating Socioeconomic, Resource and Environmental Dimensions. <i>Frontiers in Energy Research</i> , 2022, 10, . | 1.2 | 9 |
| 174 | The burden of injury in Central, Eastern, and Western European sub-region: a systematic analysis from the Global Burden of Disease 2019 Study. <i>Archives of Public Health</i> , 2022, 80, 142. | 1.0 | 9 |
| 175 | Transposition and implementation of EU rare disease policy in Eastern Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 557-566. | 0.7 | 8 |
| 176 | Alcohol Beverage Household Expenditure, Taxation and Government Revenues in Broader European WHO Region. <i>Frontiers in Pharmacology</i> , 2017, 8, 303. | 1.6 | 8 |
| 177 | Editorial: Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies. <i>Frontiers in Pharmacology</i> , 2017, 8, 662. | 1.6 | 8 |
| 178 | Fraudster™s and victims™ profiles and loss predictors™ hierarchy in the mental healthcare industry in the US. <i>Journal of Medical Economics</i> , 2020, 23, 1111-1122. | 1.0 | 8 |
| 179 | Long Term Dental Work Force Build-Up and DMFT-12 Improvement in the European Region. <i>Frontiers in Physiology</i> , 2016, 7, 48. | 1.3 | 7 |
| 180 | Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. <i>BioMed Research International</i> , 2021, 2021, 1-16. | 0.9 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Aging and Global Health. , 2021, , 73-102. | | 6 |
| 182 | Cost-effectiveness of depressive episode pharmacological treatment. Hospital Pharmacology, 2015, 2, 235-245. | 0.1 | 6 |
| 183 | How Fast Are the Asian Countries Progressing Toward Green Economy? Implications for Public Health. Frontiers in Public Health, 2021, 9, 753338. | 1.3 | 6 |
| 184 | Inhibitory effects of selected antiepileptics on spontaneous motility of isolated human oviducts. European Journal of Clinical Pharmacology, 2006, 62, 707-712. | 0.8 | 5 |
| 185 | Cost Analysis of Health Examination Screening Program for Ischemic Heart Disease in Active-Duty Military Personnel in the Middle-Income Country. Frontiers in Public Health, 2021, 9, 634778. | 1.3 | 5 |
| 186 | Predictors of loss due to pharmaceutical fraud: evidence from the U.S.. Cost Effectiveness and Resource Allocation, 2022, 20, 6. | 0.6 | 5 |
| 187 | Cranio-cerebral injuries in traffic accidents with fatal outcomes. Australian Journal of Forensic Sciences, 2014, 46, 180-193. | 0.7 | 4 |
| 188 | Regulatory Issues Surrounding Audit of Electronic Cigarette Charge Composition. Frontiers in Psychiatry, 2015, 6, 133. | 1.3 | 4 |
| 189 | Medical Cost of Colorectal Cancer Services in Serbia Between 2014 and 2017: National Data Report. Frontiers in Pharmacology, 2019, 10, 526. | 1.6 | 4 |
| 190 | Cost of illness of community-acquired pneumonia. Review of the literature and possible strategies in the Serbian health care setting. Farmeconomia E Percorsi Terapeutici, 2012, 13, 133-139. | 0.2 | 4 |
| 191 | Disempowered Mothers Have Undernourished Children: How Strong Is the Intrinsic Agency?. Frontiers in Public Health, 2022, 10, 817717. | 1.3 | 4 |
| 192 | A comment on the article: StoÅiÄ S, KaranoviÄ N. Health care economics in Serbia: current problems and changes. Vojnosanit Pregl 2014; 71(11): 1055-1061. Vojnosanitetski Pregled, 2015, 72, 203-5. | 0.1 | 4 |
| 193 | Intentional Self-Poisonings and Unintentional Poisonings of Adolescents With Nonfatal Outcomes. Journal of Child and Adolescent Substance Abuse, 2015, 24, 12-18. | 0.5 | 3 |
| 194 | Commentary: Do health care workforce, population, and service provision significantly contribute to the total health expenditure? An econometric analysis of Serbia. Frontiers in Pharmacology, 2017, 8, 33. | 1.6 | 3 |
| 195 | Caffeine consumption patterns and determinants among adolescents in Serbia. International Journal of Adolescent Medicine and Health, 2018, 30, . | 0.6 | 3 |
| 196 | Editorial: Challenges of Pharmacoeconomics in Global Health Arena. Frontiers in Public Health, 2018, 6, 368. | 1.3 | 3 |
| 197 | Dynamics of Health Care Financing and Spending in Serbia in the XXI Century. Frontiers in Public Health, 2019, 7, 381. | 1.3 | 3 |
| 198 | 10.5937/mckg48-5071 = Recent developments in the world's leading generic markets. Medicinski Casopis, 2014, 48, 140-142. | 0.1 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Hospital oncology costs among the cohort of elderly in an aging South-Eastern European nation. <i>Farmeconomia E Percorsi Terapeutici</i> , 2015, 16, 3-5. | 0.2 | 3 |
| 200 | Cost differentials of dental outpatient care across clinical dentistry branches. <i>Farmeconomia E Percorsi Terapeutici</i> , 2015, 16, 25-32. | 0.2 | 3 |
| 201 | Editorial: Universal Health Coverage: The Long Road Ahead for Low- and Middle-Income Regions. <i>Frontiers in Public Health</i> , 2021, 9, 746651. | 1.3 | 3 |
| 202 | Targeted immunotherapies overtaking emerging oncology market value based growth. <i>Journal of B U on</i> , 2015, 20, 350-1. | 0.4 | 3 |
| 203 | Editorial: Emerging Marketsâ€™ Health and Pharmaceutical Sectors at the Dawn of a Potential Global Financial Crisis of early 2020s. <i>Frontiers in Pharmacology</i> , 2022, 13, 907612. | 1.6 | 3 |
| 204 | Improvements in Neonatal and Childhood Medical Care â€œ Perspective from the Balkans. <i>Frontiers in Public Health</i> , 2015, 3, 206. | 1.3 | 2 |
| 205 | Commentary: Implementing Pro-Poor Universal Health Coverage. <i>Frontiers in Public Health</i> , 2016, 4, 186. | 1.3 | 2 |
| 206 | The Impact of the Socio-Demographic Characteristics of Complementary and Alternative Medicine Users in Serbia on OTC Drug Consumption. <i>Frontiers in Public Health</i> , 2019, 7, 303. | 1.3 | 2 |
| 207 | Editorial: Accelerated Globalization and Its Impact to the World's Health Care Achievement. <i>Frontiers in Public Health</i> , 2021, 9, 690239. | 1.3 | 2 |
| 208 | BRICs Nations Growing Impact on the Global Health Sector. <i>Vestnik MGIMO-Universiteta</i> , 2020, 12, 150-166. | 0.1 | 2 |
| 209 | Editorial: Health Financing and Spending in Low- and Middle-Income Countries. <i>Frontiers in Public Health</i> , 2021, 9, 800333. | 1.3 | 2 |
| 210 | Editorial: Fraud and Corruption in Healthcare. <i>Frontiers in Public Health</i> , 2022, 10, . | 1.3 | 2 |
| 211 | Environmental Pollution Liability Insurance of Health Risk and Corporate Environmental Performance: Evidence From China. <i>Frontiers in Public Health</i> , 0, 10, . | 1.3 | 2 |
| 212 | Aging and Global Health. , 2020, , 1-30. | | 1 |
| 213 | Highlighting the Role of Universally Available and Innate Immune Cell Counts in Acute Ischemic Stroke: A Scoping Review. <i>Sustainability</i> , 2021, 13, 4069. | 1.6 | 1 |
| 214 | Blood alcohol concentration impact on the traffic accident rates with fatal outcome. <i>Medicinski Casopis</i> , 2012, 46, 160-167. | 0.1 | 1 |
| 215 | Global article collection: essential reads from around the world. <i>Journal of Medical Economics</i> , 2022, 25, 864-869. | 1.0 | 1 |
| 216 | Systematic Review of Existing Stroke Guidelines: Case for a Change. <i>BioMed Research International</i> , 2022, 2022, 1-11. | 0.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Happiness: A Novel Outcome Measure in Stroke?. Therapeutics and Clinical Risk Management, 2021, Volume 17, 747-754. | 0.9 | 0 |
| 218 | Role of anticonvulsant therapeutic drug monitoring in improving clinical outcomes: An example of 12 adult epilepsy patients. Serbian Journal of Experimental and Clinical Research, 2012, 13, 68-71. | 0.2 | 0 |
| 219 | Direct costs of treating community-acquired pneumonia do not necessarily correlate with clinical severity. , 2015, , . | | 0 |